|
KR20200136430A
|
|
Use of alginate oligomers to enhance the potential of micro/nanoparticles across mucus layers
|
|
GB201812473D0
|
|
Method for the qualitative and quantitative detection of alginate oligomers in body fluids
|
|
GB201808477D0
|
|
Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense micorstruture
|
|
GB201806495D0
|
|
Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers
|
|
KR20190072579A
|
|
Polymyxin-Alginate Oligomer Conjugate
|
|
GB201714710D0
|
|
Polymyxin-alginate oligomer conjugates
|
|
GB201708325D0
|
|
Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots wich have an abrnormally dense microstructure
|
|
GB201702161D0
|
|
A companion diagnostic method for use in the treatment of cystic fibrosis with alginate oligomers
|
|
GB201617860D0
|
|
Polymyxin-alginate oligomer conjugates
|
|
GB201617862D0
|
|
Bacitracin-alginate oligomer conjugates
|
|
GB201517639D0
|
|
Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
|
|
GB201504878D0
|
|
Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
|
|
KR20160119259A
|
|
Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
|
|
GB201502110D0
|
|
Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function
|
|
GB201415381D0
|
|
Inhalable powder formulations of alginate oligomers
|
|
GB201403630D0
|
|
Treatment of cystic fibrosis with alginate oligomers
|
|
GB201322777D0
|
|
Use of alginate oligomers as blood anticoagulants
|
|
GB201118420D0
|
|
Immunostimulatory alginates
|
|
GB201116010D0
|
|
Use of alginate oligomers to enhance the effects of antifungal agents
|
|
EP2437783A1
|
|
Treatment of acinetobacter with alginate oligomers and antibiotics
|
